| Reshma Kewalramani |
CEO & President, Director |
$55.7 M |
-$21.2 M |
-27.6% |
May 24, 2024 |
| Amit Sachdev |
EVP Chief Patient & Ext Af Off |
$26.8 M |
-$9.31 M |
-25.8% |
Jun 5, 2024 |
| Bruce I. Sachs |
Director |
$24.3 M |
-$11.5 M |
-32.2% |
May 22, 2024 |
| Ourania Tatsis |
EVP, Chief Reg. & Quality Off. |
$22.6 M |
-$6.55 M |
-22.5% |
Jun 3, 2024 |
| Charles F. Wagner Jr |
EVP & Chief Financial Officer |
$21.7 M |
-$5.24 M |
-19.5% |
Jun 3, 2024 |
| Stuart A. Arbuckle |
Evp, Coo |
$21.5 M |
-$11 M |
-33.8% |
May 15, 2024 |
| Carmen Bozic |
EVP and CMO |
$14.2 M |
-$15.4 M |
-52% |
Jun 26, 2024 |
| Bastiano Sanna |
EVP, Cell & Genetic Therapies |
$13.4 M |
|
|
May 5, 2023 |
| David Altshuler |
EVP, Chief Scientific Officer |
$11.1 M |
-$6.13 M |
-35.5% |
May 15, 2024 |
| Jonathan Biller |
EVP and Chief Legal Officer |
$7.66 M |
-$939 K |
-10.9% |
Feb 9, 2024 |
| Edward Morrow Atkinson III |
EVP, Chief Technical Ops. Off. |
$7.63 M |
-$5.09 M |
-40% |
Jun 11, 2024 |
| Jeffrey M. Leiden |
Executive Chairman, Director |
$5.98 M |
-$18.2 M |
-75.2% |
Feb 20, 2024 |
| Joy Liu |
SVP, General Counsel |
$4.03 M |
|
|
Aug 15, 2022 |
| Diana Mckenzie |
Director |
$3.48 M |
|
|
May 1, 2024 |
| Kristen Ambrose |
SVP & Chief Accounting Officer |
$3.14 M |
-$1.05 M |
-25.1% |
Apr 1, 2024 |
| Terrence C. Kearney |
Director |
$3.14 M |
-$3.5 M |
-52.7% |
May 1, 2024 |
| Margaret G. Mcglynn |
Director |
$2.95 M |
|
|
May 1, 2023 |
| Lloyd Carney |
Director |
$2.55 M |
|
|
May 1, 2024 |
| Sangeeta N. Bhatia |
Director |
$1.79 M |
-$450 K |
-20.1% |
May 1, 2024 |
| Suketu Upadhyay |
Director |
$1.6 M |
|
|
May 1, 2024 |
| Yuchun Lee |
Director |
$1.23 M |
|
|
May 1, 2023 |
| Michel Lagarde |
Director |
$875 K |
|
|
May 1, 2024 |
| Nancy Thornberry |
Director |
$860 K |
|
|
May 1, 2024 |
| Alan M. Garber |
Director |
$401 K |
|
|
May 1, 2024 |
| Jennifer Schneider |
Director |
$372 K |
|
|
May 15, 2024 |